Anzeige
Mehr »
Sonntag, 31.08.2025 - Börsentäglich über 12.000 News
SuperBuzz: Die KI-Aktie, die man sich jetzt zum Ende des Sommers nicht entgehen lassen darf
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A402W6 | ISIN: US5019761049 | Ticker-Symbol:
NASDAQ
29.08.25 | 21:44
3,735 US-Dollar
+0,95 % +0,035
1-Jahres-Chart
KYVERNA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
KYVERNA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur KYVERNA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoKyverna Therapeutics, Inc.: Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event121KYV-101 has the potential to deliver durable, drug-free, disease-free remission in myasthenia gravis and set a new treatment standard for stiff person syndrome Innovative FDA-aligned KYSA-6 Phase...
► Artikel lesen
KYVERNA THERAPEUTICS Aktie jetzt für 0€ handeln
20.08.Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 20263
20.08.William Blair initiates coverage on Kyverna Therapeutics stock with Outperform rating1
20.08.William Blair startet Coverage für Kyverna mit "Outperform"-Rating und Kursziel von 27 US-Dollar3
12.08.Kyverna Therapeutics GAAP EPS of -$0.97 beats by $0.073
12.08.Kyverna Therapeutics, Inc. - 10-Q, Quarterly Report3
12.08.Kyverna Therapeutics, Inc. - 8-K, Current Report1
12.08.Kyverna Therapeutics, Inc.: Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results259Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) andBLA submission anticipated in 1H 2026 Registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) to include...
► Artikel lesen
30.06.Kyverna Therapeutics appoints Marc Grasso as CFO6
30.06.Kyverna therapeutics appoints Marc Grasso as new chief financial officer1
30.06.Kyverna Therapeutics, Inc. - 8-K, Current Report3
03.06.Kyverna Therapeutics, Inc. - 8-K, Current Report9
27.05.With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?4
14.05.Kyverna Therapeutics GAAP EPS of -$1.032
14.05.Kyverna lays off 16% of staff as autoimmune CAR-T plans pick up pace6
13.05.Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results110Enrollment complete in registrational Phase 2 KYV-101 trial in stiff person syndrome (SPS); on track for topline data in 1H 2026; biologics license application (BLA)...
► Artikel lesen
27.03.Kyverna Therapeutics files for $250M mixed securities shelf4
27.03.Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results1.030Accelerating clinical path to commercialization in stiff person syndrome, myasthenia gravis and lupus nephritis Aligned with the U.S. Food and Drug Administration...
► Artikel lesen
27.03.Kyverna Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
27.03.Kyverna Therapeutics, Inc. - 10-K, Annual Report3
Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1